Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Consensus Recommendation of “Hold” from Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received a consensus rating of “Hold” from the five ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $41.00.

A number of brokerages have weighed in on ETON. Zacks Research lowered shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. B. Riley Financial raised their target price on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. Finally, Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $32.15 on Tuesday. Eton Pharmaceuticals has a fifty-two week low of $13.09 and a fifty-two week high of $35.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. The firm has a market capitalization of $880.59 million, a P/E ratio of -459.22 and a beta of 0.87. The company’s 50 day moving average price is $28.50 and its two-hundred day moving average price is $21.25.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The company had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. On average, equities analysts forecast that Eton Pharmaceuticals will post 0.75 earnings per share for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other news, insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the transaction, the insider owned 25,249 shares in the company, valued at approximately $843,064.11. The trade was a 62.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 100,000 shares of company stock worth $3,229,921 in the last quarter. 16.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of hedge funds have recently modified their holdings of ETON. Quarry LP acquired a new position in shares of Eton Pharmaceuticals during the third quarter worth $37,000. Legal & General Group Plc acquired a new position in Eton Pharmaceuticals in the second quarter valued at $41,000. Caitong International Asset Management Co. Ltd acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at $44,000. China Universal Asset Management Co. Ltd. acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at $74,000. Finally, SG Americas Securities LLC acquired a new position in Eton Pharmaceuticals in the fourth quarter valued at $109,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.